In conclusion, KCTD10 suppresses lung cancer metastasis and tumor angiogenesis by interacting with β-catenin to promote its ubiquitin-dependent degradation, which then inhibits EMT and PD-L1 expression, leading to the improving outcome of anti-PD-1 therapy. Here, KCTD10 is linked to lung cancer.